

## Special Issue

# The Long Reach of the Retinoblastoma Tumor Suppressor Pathway

### Message from the Guest Editors

The conventional retinoblastoma tumor suppressor (RB) pathway was defined over 25 years ago. While the subject has been intensely studied and plays a well-established role in cell cycle control, the biological impact of the RB-pathway has continued to expand. Recent studies have illustrated roles for RB in a spectrum of diverse, context-selective biology including cancer lineage states, metabolic programs, and immune responses. These findings have induced a re-appraisal of the mechanisms through which RB functions control gene expression beyond E2F transcription factors. Furthermore, it has become clear that the RB-pathway is a key determinant of tumor progression and therapeutic response. While CDK4/6 inhibitors directly impinge on RB, complex regulatory networks involving the RB-pathway are relevant for therapeutic responses or the emergence of acquired resistance in a number of distinct contexts. This Special Issue explores new findings related to the breadth of the RB-pathway in tumor biology and therapy.

---

### Guest Editors

Prof. Dr. Erik Knudsen

Dr. David W. Goodrich

Dr. Agnieszka Witkiewicz

Dr. Ioannis Sanidas

---

### Deadline for manuscript submissions

closed (30 May 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/157974](https://mdpi.com/si/157974)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)